{"id":952546,"date":"2026-04-17T10:51:57","date_gmt":"2026-04-17T14:51:57","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/slno-shareholder-alert-investors-with-losses-may-seek-to-lead-the-class-action-in-soleno-therapeutics-inc-securities-lawsuit-the-gross-law-firm-2\/"},"modified":"2026-04-17T10:51:57","modified_gmt":"2026-04-17T14:51:57","slug":"slno-shareholder-alert-investors-with-losses-may-seek-to-lead-the-class-action-in-soleno-therapeutics-inc-securities-lawsuit-the-gross-law-firm-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/slno-shareholder-alert-investors-with-losses-may-seek-to-lead-the-class-action-in-soleno-therapeutics-inc-securities-lawsuit-the-gross-law-firm-2\/","title":{"rendered":"SLNO Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Soleno Therapeutics, Inc. Securities Lawsuit \u2014 The Gross Law Firm"},"content":{"rendered":"<div class=\"mw_release\">\n<p>NEW YORK, April  17, 2026  (GLOBE NEWSWIRE) &#8212; The Gross Law Firm issues the following notice to shareholders of <strong>Soleno Therapeutics, Inc. (NASDAQ: SLNO).<\/strong><\/p>\n<p>Shareholders who purchased shares of SLNO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.<\/p>\n<p align=\"center\">CONTACT US HERE:<\/p>\n<p align=\"center\">\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FI43sMtWYoLeWyLecJ9vLQGrsLp_CWZZTz84NqfhcPQzsMtxhswr1DMOY0kHNAO7hEePyL0rfNSy9Z9ojajkfKy-IbtLQFQRndAL8RgC5ga0IcShDUvoEEqNSlk4UTyWJZlP2qINcwBbJ6l7Q8cqHJ7iV92CiACxiT5ZTZow1MG-ajUppMyLp26uTfO_0-8UElBMedD0JB-rZIueKbpkh7RvhNDVBIDV42l1Su_arjhNqz6mwYhNqtZ3zJVyqlCznPsB_DVjCGNjQQ53UZmxHVMIXNtnV9F8SZbN002PJVo0M0mINBCe5698K7qyB7wL\" rel=\"nofollow\" target=\"_blank\">https:\/\/securitiesclasslaw.com\/securities\/soleno-therapeutics-inc-loss-submission-form\/?id=185573&amp;from=3<\/a>\u00a0<\/p>\n<p>\n        <strong>CLASS PERIOD: <\/strong>March 26, 2025 to November 4, 2025<\/p>\n<p>\n        <strong>ALLEGATIONS: <\/strong>The complaint alleges that during the class period, Defendants issued materially false and\/or misleading statements and\/or failed to disclose that: (a) the Soleno Phase 3 clinical trial program for product diazoxide choline extended-release tablets, DCCR, had systematically downplayed, misrepresented, and\/or concealed significant evidence of safety concerns potentially related to the administration of DCCR, including issues related to excess fluid retention in clinical trial participants; (b) as a result of (a) above, the administration of DCCR to treat hyperphagia in individuals with PWS posed materially greater safety risks than disclosed by the Company or its executives; and (c) as a result of (a)-(b) above, DCCR had materially lower commercial viability and undisclosed risks related to the likelihood of significant and widespread adverse events after its commercial launch, including risks related to patient discontinuation rates, lower patient adoption, prescriber reluctance, adverse regulatory action, and potential reputational and legal fallout.<\/p>\n<p>\n        <strong>DEADLINE: May 5, 2026<\/strong> Shareholders should not delay in registering for this class action. Register your information here: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FI43sMtWYoLeWyLecJ9vLQGrsLp_CWZZTz84NqfhcPQzsMtxhswr1DMOY0kHNAO7hEePyL0rfNSy9Z9ojajkfKy-IbtLQFQRndAL8RgC5ga0IcShDUvoEEqNSlk4UTyWJZlP2qINcwBbJ6l7Q8cqHCon65rNASl6But1ZGdHavGGmbqw1O0KC_vC5VuhAUGyIzgH4e9IfNJaueNR505k1vvZLyPGc-yG5tTUXC7_kQgiJn9fQNttoKAkBjklZUpZ61pKkSruFWas36hPI7Q0qrdR_9wznhdEEDBWWAeZ21tpQPWZCTiDWqpo5hxclGS5\" rel=\"nofollow\" target=\"_blank\">https:\/\/securitiesclasslaw.com\/securities\/soleno-therapeutics-inc-loss-submission-form\/?id=185573&amp;from=3<\/a>\u00a0<\/p>\n<p>\n        <strong>NEXT STEPS FOR SHAREHOLDERS: <\/strong>Once you register as a shareholder who purchased shares of SLNO during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is May 5, 2026. There is no cost or obligation to you to participate in this case.<\/p>\n<p>\n        <strong>WHY GROSS LAW FIRM? <\/strong>The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and\/or misleading statements or the omission of material information by a company lead to artificial inflation of the company&#8217;s stock. Attorney advertising. Prior results do not guarantee similar outcomes.<\/p>\n<p>\n        <strong>CONTACT:<\/strong><br \/>\n        <br \/>The Gross Law Firm<br \/>15 West 38th Street, 12th floor<br \/>New York, NY, 10018<br \/>Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IfHOPrFZEDykeXPzH7CS091VwevElc_g-kMy8FnxatP907XlPzH9iukG1wBsFewyvA_yfDQeQSaZhmYZwYqW_C17upS0_lyL8Cj9gKS5AODmCBbuRDvuL3XXLtv1-P7I\" rel=\"nofollow\" target=\"_blank\">dg@securitiesclasslaw.com<\/a>\u00a0<br \/>Phone: (646) 453-8903<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MTUzNiM3NTQwMTk1IzIyNTg5MTc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NDFjMzFjMjUtNDhkZi00ZWNjLWI4YmEtMDdkMDg5ODliYzhjLTEyNzA0NjctMjAyNi0wNC0xNy1lbg==\/tiny\/The-Gross-Law-Firm.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) &#8212; The Gross Law Firm issues the following notice to shareholders of Soleno Therapeutics, Inc. (NASDAQ: SLNO). Shareholders who purchased shares of SLNO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https:\/\/securitiesclasslaw.com\/securities\/soleno-therapeutics-inc-loss-submission-form\/?id=185573&amp;from=3\u00a0 CLASS PERIOD: March 26, 2025 to November 4, 2025 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and\/or misleading statements and\/or failed to disclose that: (a) the Soleno Phase 3 clinical trial program for product diazoxide choline extended-release tablets, DCCR, had systematically downplayed, misrepresented, and\/or concealed significant evidence of safety concerns potentially related &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/slno-shareholder-alert-investors-with-losses-may-seek-to-lead-the-class-action-in-soleno-therapeutics-inc-securities-lawsuit-the-gross-law-firm-2\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;SLNO Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Soleno Therapeutics, Inc. Securities Lawsuit \u2014 The Gross Law Firm&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-952546","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>SLNO Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Soleno Therapeutics, Inc. Securities Lawsuit \u2014 The Gross Law Firm - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/slno-shareholder-alert-investors-with-losses-may-seek-to-lead-the-class-action-in-soleno-therapeutics-inc-securities-lawsuit-the-gross-law-firm-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SLNO Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Soleno Therapeutics, Inc. Securities Lawsuit \u2014 The Gross Law Firm - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) &#8212; The Gross Law Firm issues the following notice to shareholders of Soleno Therapeutics, Inc. (NASDAQ: SLNO). Shareholders who purchased shares of SLNO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https:\/\/securitiesclasslaw.com\/securities\/soleno-therapeutics-inc-loss-submission-form\/?id=185573&amp;from=3\u00a0 CLASS PERIOD: March 26, 2025 to November 4, 2025 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and\/or misleading statements and\/or failed to disclose that: (a) the Soleno Phase 3 clinical trial program for product diazoxide choline extended-release tablets, DCCR, had systematically downplayed, misrepresented, and\/or concealed significant evidence of safety concerns potentially related &hellip; Continue reading &quot;SLNO Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Soleno Therapeutics, Inc. Securities Lawsuit \u2014 The Gross Law Firm&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/slno-shareholder-alert-investors-with-losses-may-seek-to-lead-the-class-action-in-soleno-therapeutics-inc-securities-lawsuit-the-gross-law-firm-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-17T14:51:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MTUzNiM3NTQwMTk1IzIyNTg5MTc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/slno-shareholder-alert-investors-with-losses-may-seek-to-lead-the-class-action-in-soleno-therapeutics-inc-securities-lawsuit-the-gross-law-firm-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/slno-shareholder-alert-investors-with-losses-may-seek-to-lead-the-class-action-in-soleno-therapeutics-inc-securities-lawsuit-the-gross-law-firm-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"SLNO Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Soleno Therapeutics, Inc. Securities Lawsuit \u2014 The Gross Law Firm\",\"datePublished\":\"2026-04-17T14:51:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/slno-shareholder-alert-investors-with-losses-may-seek-to-lead-the-class-action-in-soleno-therapeutics-inc-securities-lawsuit-the-gross-law-firm-2\\\/\"},\"wordCount\":458,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/slno-shareholder-alert-investors-with-losses-may-seek-to-lead-the-class-action-in-soleno-therapeutics-inc-securities-lawsuit-the-gross-law-firm-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5MTUzNiM3NTQwMTk1IzIyNTg5MTc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/slno-shareholder-alert-investors-with-losses-may-seek-to-lead-the-class-action-in-soleno-therapeutics-inc-securities-lawsuit-the-gross-law-firm-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/slno-shareholder-alert-investors-with-losses-may-seek-to-lead-the-class-action-in-soleno-therapeutics-inc-securities-lawsuit-the-gross-law-firm-2\\\/\",\"name\":\"SLNO Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Soleno Therapeutics, Inc. Securities Lawsuit \u2014 The Gross Law Firm - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/slno-shareholder-alert-investors-with-losses-may-seek-to-lead-the-class-action-in-soleno-therapeutics-inc-securities-lawsuit-the-gross-law-firm-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/slno-shareholder-alert-investors-with-losses-may-seek-to-lead-the-class-action-in-soleno-therapeutics-inc-securities-lawsuit-the-gross-law-firm-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5MTUzNiM3NTQwMTk1IzIyNTg5MTc=\",\"datePublished\":\"2026-04-17T14:51:57+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/slno-shareholder-alert-investors-with-losses-may-seek-to-lead-the-class-action-in-soleno-therapeutics-inc-securities-lawsuit-the-gross-law-firm-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/slno-shareholder-alert-investors-with-losses-may-seek-to-lead-the-class-action-in-soleno-therapeutics-inc-securities-lawsuit-the-gross-law-firm-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/slno-shareholder-alert-investors-with-losses-may-seek-to-lead-the-class-action-in-soleno-therapeutics-inc-securities-lawsuit-the-gross-law-firm-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5MTUzNiM3NTQwMTk1IzIyNTg5MTc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5MTUzNiM3NTQwMTk1IzIyNTg5MTc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/slno-shareholder-alert-investors-with-losses-may-seek-to-lead-the-class-action-in-soleno-therapeutics-inc-securities-lawsuit-the-gross-law-firm-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SLNO Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Soleno Therapeutics, Inc. Securities Lawsuit \u2014 The Gross Law Firm\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SLNO Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Soleno Therapeutics, Inc. Securities Lawsuit \u2014 The Gross Law Firm - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/slno-shareholder-alert-investors-with-losses-may-seek-to-lead-the-class-action-in-soleno-therapeutics-inc-securities-lawsuit-the-gross-law-firm-2\/","og_locale":"en_US","og_type":"article","og_title":"SLNO Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Soleno Therapeutics, Inc. Securities Lawsuit \u2014 The Gross Law Firm - Market Newsdesk","og_description":"NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) &#8212; The Gross Law Firm issues the following notice to shareholders of Soleno Therapeutics, Inc. (NASDAQ: SLNO). Shareholders who purchased shares of SLNO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https:\/\/securitiesclasslaw.com\/securities\/soleno-therapeutics-inc-loss-submission-form\/?id=185573&amp;from=3\u00a0 CLASS PERIOD: March 26, 2025 to November 4, 2025 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and\/or misleading statements and\/or failed to disclose that: (a) the Soleno Phase 3 clinical trial program for product diazoxide choline extended-release tablets, DCCR, had systematically downplayed, misrepresented, and\/or concealed significant evidence of safety concerns potentially related &hellip; Continue reading \"SLNO Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Soleno Therapeutics, Inc. Securities Lawsuit \u2014 The Gross Law Firm\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/slno-shareholder-alert-investors-with-losses-may-seek-to-lead-the-class-action-in-soleno-therapeutics-inc-securities-lawsuit-the-gross-law-firm-2\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-17T14:51:57+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MTUzNiM3NTQwMTk1IzIyNTg5MTc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/slno-shareholder-alert-investors-with-losses-may-seek-to-lead-the-class-action-in-soleno-therapeutics-inc-securities-lawsuit-the-gross-law-firm-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/slno-shareholder-alert-investors-with-losses-may-seek-to-lead-the-class-action-in-soleno-therapeutics-inc-securities-lawsuit-the-gross-law-firm-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"SLNO Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Soleno Therapeutics, Inc. Securities Lawsuit \u2014 The Gross Law Firm","datePublished":"2026-04-17T14:51:57+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/slno-shareholder-alert-investors-with-losses-may-seek-to-lead-the-class-action-in-soleno-therapeutics-inc-securities-lawsuit-the-gross-law-firm-2\/"},"wordCount":458,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/slno-shareholder-alert-investors-with-losses-may-seek-to-lead-the-class-action-in-soleno-therapeutics-inc-securities-lawsuit-the-gross-law-firm-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MTUzNiM3NTQwMTk1IzIyNTg5MTc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/slno-shareholder-alert-investors-with-losses-may-seek-to-lead-the-class-action-in-soleno-therapeutics-inc-securities-lawsuit-the-gross-law-firm-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/slno-shareholder-alert-investors-with-losses-may-seek-to-lead-the-class-action-in-soleno-therapeutics-inc-securities-lawsuit-the-gross-law-firm-2\/","name":"SLNO Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Soleno Therapeutics, Inc. Securities Lawsuit \u2014 The Gross Law Firm - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/slno-shareholder-alert-investors-with-losses-may-seek-to-lead-the-class-action-in-soleno-therapeutics-inc-securities-lawsuit-the-gross-law-firm-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/slno-shareholder-alert-investors-with-losses-may-seek-to-lead-the-class-action-in-soleno-therapeutics-inc-securities-lawsuit-the-gross-law-firm-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MTUzNiM3NTQwMTk1IzIyNTg5MTc=","datePublished":"2026-04-17T14:51:57+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/slno-shareholder-alert-investors-with-losses-may-seek-to-lead-the-class-action-in-soleno-therapeutics-inc-securities-lawsuit-the-gross-law-firm-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/slno-shareholder-alert-investors-with-losses-may-seek-to-lead-the-class-action-in-soleno-therapeutics-inc-securities-lawsuit-the-gross-law-firm-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/slno-shareholder-alert-investors-with-losses-may-seek-to-lead-the-class-action-in-soleno-therapeutics-inc-securities-lawsuit-the-gross-law-firm-2\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MTUzNiM3NTQwMTk1IzIyNTg5MTc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MTUzNiM3NTQwMTk1IzIyNTg5MTc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/slno-shareholder-alert-investors-with-losses-may-seek-to-lead-the-class-action-in-soleno-therapeutics-inc-securities-lawsuit-the-gross-law-firm-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"SLNO Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Soleno Therapeutics, Inc. Securities Lawsuit \u2014 The Gross Law Firm"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/952546","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=952546"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/952546\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=952546"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=952546"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=952546"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}